What is the projected market valuation of the Mycological Testing Market by 2035?

The Mycological Testing Market is projected to reach a valuation of 5.627 USD Billion by 2035. Read More

What was the market valuation of the Mycological Testing Market in 2024?

In 2024, the Mycological Testing Market was valued at 2.468 USD Billion. Read More

What is the expected CAGR for the Mycological Testing Market during the forecast period 2025 - 2035?

The expected CAGR for the Mycological Testing Market during the forecast period 2025 - 2035 is 7.78%. Read More

Which companies are considered key players in the Mycological Testing Market?

Key players in the Mycological Testing Market include Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, and Neogen Corporation. Read More

What are the main segments of the Mycological Testing Market based on specimen type?

The main segments based on specimen type include Tissue, Fluid, and Culture, with valuations of 1.7405, 1.1935, and 2.693 USD Billion respectively by 2035. Read More

How does the market for fungi detection compare to other pathogens in 2035?

By 2035, the market for fungi detection is projected to reach 1.5 USD Billion, compared to 1.4 USD Billion for viruses and 1.7 USD Billion for bacteria. Read More

What test methods are utilized in the Mycological Testing Market?

The test methods utilized include Microscopy, Culture, Molecular, and Immunological, with projected valuations of 1.7245 USD Billion for Culture and Molecular by 2035. Read More

What applications drive the Mycological Testing Market?

Key applications driving the market include Infectious Disease Diagnosis, Antimicrobial Susceptibility Testing, and Food Safety Testing, with the latter expected to reach 2.627 USD Billion by 2035. Read More

What is the projected growth for the environmental specimen source segment by 2035?

The environmental specimen source segment is projected to grow to 1.1645 USD Billion by 2035. Read More

How does the Mycological Testing Market's growth reflect on the overall healthcare landscape?

The growth of the Mycological Testing Market indicates a rising emphasis on diagnostics and safety in healthcare, particularly with a projected increase in demand for testing applications. Read More

Mycological Testing Market

ID: MRFR/HC/39016-HCR 100 Pages Rahul Gotadki Last Updated: September 17, 2026

Mycological Testing Market Research Report: Size, Share, Trend Analysis By Types of Specimen (Tissue, Fluid, Culture), By Pathogen Detected (Bacteria, Virus, Fungi, Parasite), By Test Method (Microscopy, Culture, Molecular, Immunological), By Specimen Source (Clinical, Environmental, Veterinary), By Applications (Infectious Disease Diagnosis, Antimicrobial Susceptibility Testing, Food Safety Testing) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Mycological Testing Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)7.78%

2024 Market Size$ 2.47 Billion

2025 Market Size$ 2.66 Billion

2035 Market Size$ 5.63 Billion

Key Players

Thermo Fisher Scientific

Merck KGaA

Bio-Rad Laboratories

Neogen Corporation

Romer Labs

Becton

Trends

Technological Advancements
Increased Awareness of Fungal Infections
Regulatory Changes and Standards

Opportunities

Rising Incidence of Fungal Infections
Increased Focus on Preventive Healthcare
Regulatory Support for Diagnostic Testing

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type of Specimen (USD Billion)
  1. 4.1.1 Tissue
  2. 4.1.2 Fluid
  3. 4.1.3 Culture
2. 4.2 Healthcare, BY Pathogen Detected (USD Billion)
  1. 4.2.1 Bacteria
  2. 4.2.2 Virus
  3. 4.2.3 Fungi
  4. 4.2.4 Parasite
3. 4.3 Healthcare, BY Test Method (USD Billion)
  1. 4.3.1 Microscopy
  2. 4.3.2 Culture
  3. 4.3.3 Molecular
  4. 4.3.4 Immunological
4. 4.4 Healthcare, BY Specimen Source (USD Billion)
  1. 4.4.1 Clinical
  2. 4.4.2 Environmental
  3. 4.4.3 Veterinary
5. 4.5 Healthcare, BY Application (USD Billion)
  1. 4.5.1 Infectious Disease Diagnosis
  2. 4.5.2 Antimicrobial Susceptibility Testing
  3. 4.5.3 Food Safety Testing
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Thermo Fisher Scientific (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck KGaA (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bio-Rad Laboratories (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Neogen Corporation (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Romer Labs (AT)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Becton, Dickinson and Company (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Agilent Technologies (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Charles River Laboratories (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE OF SPECIMEN
4. 6.4 US MARKET ANALYSIS BY PATHOGEN DETECTED
5. 6.5 US MARKET ANALYSIS BY TEST METHOD
6. 6.6 US MARKET ANALYSIS BY SPECIMEN SOURCE
7. 6.7 US MARKET ANALYSIS BY APPLICATION
8. 6.8 CANADA MARKET ANALYSIS BY TYPE OF SPECIMEN
9. 6.9 CANADA MARKET ANALYSIS BY PATHOGEN DETECTED
10. 6.10 CANADA MARKET ANALYSIS BY TEST METHOD
11. 6.11 CANADA MARKET ANALYSIS BY SPECIMEN SOURCE
12. 6.12 CANADA MARKET ANALYSIS BY APPLICATION
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY TYPE OF SPECIMEN
15. 6.15 GERMANY MARKET ANALYSIS BY PATHOGEN DETECTED
16. 6.16 GERMANY MARKET ANALYSIS BY TEST METHOD
17. 6.17 GERMANY MARKET ANALYSIS BY SPECIMEN SOURCE
18. 6.18 GERMANY MARKET ANALYSIS BY APPLICATION
19. 6.19 UK MARKET ANALYSIS BY TYPE OF SPECIMEN
20. 6.20 UK MARKET ANALYSIS BY PATHOGEN DETECTED
21. 6.21 UK MARKET ANALYSIS BY TEST METHOD
22. 6.22 UK MARKET ANALYSIS BY SPECIMEN SOURCE
23. 6.23 UK MARKET ANALYSIS BY APPLICATION
24. 6.24 FRANCE MARKET ANALYSIS BY TYPE OF SPECIMEN
25. 6.25 FRANCE MARKET ANALYSIS BY PATHOGEN DETECTED
26. 6.26 FRANCE MARKET ANALYSIS BY TEST METHOD
27. 6.27 FRANCE MARKET ANALYSIS BY SPECIMEN SOURCE
28. 6.28 FRANCE MARKET ANALYSIS BY APPLICATION
29. 6.29 RUSSIA MARKET ANALYSIS BY TYPE OF SPECIMEN
30. 6.30 RUSSIA MARKET ANALYSIS BY PATHOGEN DETECTED
31. 6.31 RUSSIA MARKET ANALYSIS BY TEST METHOD
32. 6.32 RUSSIA MARKET ANALYSIS BY SPECIMEN SOURCE
33. 6.33 RUSSIA MARKET ANALYSIS BY APPLICATION
34. 6.34 ITALY MARKET ANALYSIS BY TYPE OF SPECIMEN
35. 6.35 ITALY MARKET ANALYSIS BY PATHOGEN DETECTED
36. 6.36 ITALY MARKET ANALYSIS BY TEST METHOD
37. 6.37 ITALY MARKET ANALYSIS BY SPECIMEN SOURCE
38. 6.38 ITALY MARKET ANALYSIS BY APPLICATION
39. 6.39 SPAIN MARKET ANALYSIS BY TYPE OF SPECIMEN
40. 6.40 SPAIN MARKET ANALYSIS BY PATHOGEN DETECTED
41. 6.41 SPAIN MARKET ANALYSIS BY TEST METHOD
42. 6.42 SPAIN MARKET ANALYSIS BY SPECIMEN SOURCE
43. 6.43 SPAIN MARKET ANALYSIS BY APPLICATION
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE OF SPECIMEN
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY PATHOGEN DETECTED
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY TEST METHOD
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY SPECIMEN SOURCE
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY TYPE OF SPECIMEN
51. 6.51 CHINA MARKET ANALYSIS BY PATHOGEN DETECTED
52. 6.52 CHINA MARKET ANALYSIS BY TEST METHOD
53. 6.53 CHINA MARKET ANALYSIS BY SPECIMEN SOURCE
54. 6.54 CHINA MARKET ANALYSIS BY APPLICATION
55. 6.55 INDIA MARKET ANALYSIS BY TYPE OF SPECIMEN
56. 6.56 INDIA MARKET ANALYSIS BY PATHOGEN DETECTED
57. 6.57 INDIA MARKET ANALYSIS BY TEST METHOD
58. 6.58 INDIA MARKET ANALYSIS BY SPECIMEN SOURCE
59. 6.59 INDIA MARKET ANALYSIS BY APPLICATION
60. 6.60 JAPAN MARKET ANALYSIS BY TYPE OF SPECIMEN
61. 6.61 JAPAN MARKET ANALYSIS BY PATHOGEN DETECTED
62. 6.62 JAPAN MARKET ANALYSIS BY TEST METHOD
63. 6.63 JAPAN MARKET ANALYSIS BY SPECIMEN SOURCE
64. 6.64 JAPAN MARKET ANALYSIS BY APPLICATION
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE OF SPECIMEN
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY PATHOGEN DETECTED
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY TEST METHOD
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY SPECIMEN SOURCE
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
70. 6.70 MALAYSIA MARKET ANALYSIS BY TYPE OF SPECIMEN
71. 6.71 MALAYSIA MARKET ANALYSIS BY PATHOGEN DETECTED
72. 6.72 MALAYSIA MARKET ANALYSIS BY TEST METHOD
73. 6.73 MALAYSIA MARKET ANALYSIS BY SPECIMEN SOURCE
74. 6.74 MALAYSIA MARKET ANALYSIS BY APPLICATION
75. 6.75 THAILAND MARKET ANALYSIS BY TYPE OF SPECIMEN
76. 6.76 THAILAND MARKET ANALYSIS BY PATHOGEN DETECTED
77. 6.77 THAILAND MARKET ANALYSIS BY TEST METHOD
78. 6.78 THAILAND MARKET ANALYSIS BY SPECIMEN SOURCE
79. 6.79 THAILAND MARKET ANALYSIS BY APPLICATION
80. 6.80 INDONESIA MARKET ANALYSIS BY TYPE OF SPECIMEN
81. 6.81 INDONESIA MARKET ANALYSIS BY PATHOGEN DETECTED
82. 6.82 INDONESIA MARKET ANALYSIS BY TEST METHOD
83. 6.83 INDONESIA MARKET ANALYSIS BY SPECIMEN SOURCE
84. 6.84 INDONESIA MARKET ANALYSIS BY APPLICATION
85. 6.85 REST OF APAC MARKET ANALYSIS BY TYPE OF SPECIMEN
86. 6.86 REST OF APAC MARKET ANALYSIS BY PATHOGEN DETECTED
87. 6.87 REST OF APAC MARKET ANALYSIS BY TEST METHOD
88. 6.88 REST OF APAC MARKET ANALYSIS BY SPECIMEN SOURCE
89. 6.89 REST OF APAC MARKET ANALYSIS BY APPLICATION
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY TYPE OF SPECIMEN
92. 6.92 BRAZIL MARKET ANALYSIS BY PATHOGEN DETECTED
93. 6.93 BRAZIL MARKET ANALYSIS BY TEST METHOD
94. 6.94 BRAZIL MARKET ANALYSIS BY SPECIMEN SOURCE
95. 6.95 BRAZIL MARKET ANALYSIS BY APPLICATION
96. 6.96 MEXICO MARKET ANALYSIS BY TYPE OF SPECIMEN
97. 6.97 MEXICO MARKET ANALYSIS BY PATHOGEN DETECTED
98. 6.98 MEXICO MARKET ANALYSIS BY TEST METHOD
99. 6.99 MEXICO MARKET ANALYSIS BY SPECIMEN SOURCE
100. 6.100 MEXICO MARKET ANALYSIS BY APPLICATION
101. 6.101 ARGENTINA MARKET ANALYSIS BY TYPE OF SPECIMEN
102. 6.102 ARGENTINA MARKET ANALYSIS BY PATHOGEN DETECTED
103. 6.103 ARGENTINA MARKET ANALYSIS BY TEST METHOD
104. 6.104 ARGENTINA MARKET ANALYSIS BY SPECIMEN SOURCE
105. 6.105 ARGENTINA MARKET ANALYSIS BY APPLICATION
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF SPECIMEN
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATHOGEN DETECTED
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST METHOD
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY SPECIMEN SOURCE
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF SPECIMEN
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY PATHOGEN DETECTED
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY TEST METHOD
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY SPECIMEN SOURCE
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF SPECIMEN
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY PATHOGEN DETECTED
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY TEST METHOD
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY SPECIMEN SOURCE
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
122. 6.122 REST OF MEA MARKET ANALYSIS BY TYPE OF SPECIMEN
123. 6.123 REST OF MEA MARKET ANALYSIS BY PATHOGEN DETECTED
124. 6.124 REST OF MEA MARKET ANALYSIS BY TEST METHOD
125. 6.125 REST OF MEA MARKET ANALYSIS BY SPECIMEN SOURCE
126. 6.126 REST OF MEA MARKET ANALYSIS BY APPLICATION
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY TYPE OF SPECIMEN, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY TYPE OF SPECIMEN, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY PATHOGEN DETECTED, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY PATHOGEN DETECTED, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY TEST METHOD, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY TEST METHOD, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY SPECIMEN SOURCE, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY SPECIMEN SOURCE, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.2.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.2.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.2.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.2.5 BY APPLICATION, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.3.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.3.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.3.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.3.5 BY APPLICATION, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.4.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.4.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.4.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.4.5 BY APPLICATION, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.5.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.5.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.5.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.5.5 BY APPLICATION, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.6.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.6.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.6.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.6.5 BY APPLICATION, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.7.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.7.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.7.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.7.5 BY APPLICATION, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.8.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.8.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.8.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.8.5 BY APPLICATION, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.9.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.9.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.9.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.9.5 BY APPLICATION, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.10.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.10.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.10.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.10.5 BY APPLICATION, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.11.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.11.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.11.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.11.5 BY APPLICATION, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.12.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.12.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.12.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.12.5 BY APPLICATION, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.13.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.13.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.13.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.13.5 BY APPLICATION, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.14.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.14.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.14.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.14.5 BY APPLICATION, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.15.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.15.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.15.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.15.5 BY APPLICATION, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.16.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.16.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.16.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.16.5 BY APPLICATION, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.17.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.17.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.17.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.17.5 BY APPLICATION, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.18.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.18.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.18.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.18.5 BY APPLICATION, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.19.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.19.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.19.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.19.5 BY APPLICATION, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.20.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.20.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.20.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.20.5 BY APPLICATION, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.21.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.21.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.21.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.21.5 BY APPLICATION, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.22.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.22.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.22.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.22.5 BY APPLICATION, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.23.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.23.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.23.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.23.5 BY APPLICATION, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.24.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.24.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.24.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.24.5 BY APPLICATION, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.25.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.25.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.25.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.25.5 BY APPLICATION, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.26.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.26.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.26.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.26.5 BY APPLICATION, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.27.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.27.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.27.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.27.5 BY APPLICATION, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.28.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.28.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.28.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.28.5 BY APPLICATION, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.29.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.29.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.29.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.29.5 BY APPLICATION, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE OF SPECIMEN, 2025-2035 (USD Billion)
  2. 7.30.2 BY PATHOGEN DETECTED, 2025-2035 (USD Billion)
  3. 7.30.3 BY TEST METHOD, 2025-2035 (USD Billion)
  4. 7.30.4 BY SPECIMEN SOURCE, 2025-2035 (USD Billion)
  5. 7.30.5 BY APPLICATION, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Enquiry

Customize Report

Mycological Testing Market Segmentation

Mycological Testing Market By Type of Specimen (USD Billion, 2025-2035)

Tissue
Fluid
Culture

Mycological Testing Market By Pathogen Detected (USD Billion, 2025-2035)

Bacteria
Virus
Fungi
Parasite

Mycological Testing Market By Test Method (USD Billion, 2025-2035)

Microscopy
Culture
Molecular
Immunological

Mycological Testing Market By Specimen Source (USD Billion, 2025-2035)

Clinical
Environmental
Veterinary

Mycological Testing Market By Application (USD Billion, 2025-2035)

Infectious Disease Diagnosis
Antimicrobial Susceptibility Testing
Food Safety Testing

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”